The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | Moving towards a daratumumab standard of care in MM
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, discusses two clinical trials whose results have huge implications for bringing daratumumab into everyday clinical practice for multiple myeloma (MM). The ALCYONE trial (NCT02195479) recently demonstrated the superiority of bortezomib-melphalan-prednisone (VMP) with daratumumab over VMP alone for newly diagnosed MM, making VMP with daratumumab a new standard of care. Depending on the results of another trial exploring whether daratumumab improves outcome with lenalidomide and dexamethasone, this drug may become a frontline standard in elderly MM patients.
